NF-kB–p53 axis antagonism: A therapeutic opportunity in cancer treatment

References

1. American Ca ncer Society - https://www.cancer.org/treatment/treatments-and-side- effects/treatment-types/targeted-therapy. (Accessed 25 march 2022)
2. Singh H, Sen R, Baltimore D, Sharp PA, A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature. 1986;319(1986):154–8.
3. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Sig Transduct Target Ther. 2017;2;17023.
4. Yu, H, Lin L, Zhang Z. et al. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. Sig Transduct Target Ther. 2020;5:209.
5. Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 2013;12;86.
6. Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, et al. NF-κB is essential for epithelial- mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004;114(4):569–81.
7. Courtois G, Gilmore TD. Mutations in the NF-κB signaling pathway: Implications for human disease. Oncogene. 2006;25(51):6831–43.
8. Neri A, Chang CC, Lombardi L, Salina M, Corradini P, Maiolo AT, et al. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50. Cell. 1991;67(6):1075–87.
9. Zhang H, Chen Z, Miranda RN, Medeiros LJ, McCarty N. TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy. Cancer Res. 2016;76(21):6410–23.
10. Verzella D, Pescatore A, Capece D, Vecchiotti D, Ursini MV, Franzoso G, et al. Life, death, and autophagy in cancer: NF-κB turns up everywhere. Cell Death Dis. 2020;11(3):210.
11. Lane DP, Crawford LV. T antigen is bound to at host protein in SV40-transformed cells. Nature. 1979;278(5701):261–3
12. Linzer DI, Levine AJ. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 1979;17(1):43–52.
13. Bourdon JC. p53 Family isoforms. Curr Pharm Biotechnol. 2007;8(6):332–6.
14. Creative Diagnostics. p53 signaling pathway [Internet]. Shirley (NY): Creative Diagnostics. Available from: https://www.creative- diagnostics.com/p53-signaling-pathway.htm
15. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24(17):2899–908.
16. Nag S, Qin J, Srivenugopal KS, Wang M, Zhang R. The MDM2-p53 pathway revisited. J Biomed Res. 2013;27(4):254–71.
17. Shadfan M, Lopez-Pajares V, Yuan ZM. MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res. 2012;1(2):88–
18. Ozaki T, Nakagawara A. Role of p53 in cell death and human cancers. Cancers. 2011;3(1):994–1013.
19. Eldridge L. The TP53 gene and its role in cancer [Internet]. New York (NY): Verywell Health; 2025 Jan 21. Available from: https://www.verywellhealth.com/the-p53-gene-its-role-in-cancer- 2249349
20. Cen Z, Juan L Dandan X, Tianliang Z, Wenwei H, Zhaohui F. Gain- of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 2020;12(9):674-87.
21. Alvarado-Ortiz E, de la Cruz-López KG, Becerril-Rico J, Sarabia- Sánchez MA, Ortiz-Sánchez E, García-Carrancá A. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches. Front Cell Dev Biol. 2021;8:607670.
22. Nilbert M, Rydholm A, Willén H, Mitelman F, Mandahl N. MDM2 gene amplification correlates with ring chromosomes in soft tissue tumors. Genes Chromosomes Cancer. 1994;9(4):261–5.
23. Wang HQ, Mulford IJ, Sharp F, Liang J, Kurtulus S, Trabucco G, et al. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment. Cancer Res. 2021;81(11):3079–91.
24. Iannetti A, Ledoux AC, Tudhope SJ, Sellier H, Zhao B, Mowla S, et al. Regulation of p53 and Rb links the alternative NF-κB pathway to EZH2 expression and cell senescence. PLoS Genetics. 2014;10(9):e1004642.
25. Rocha S, Campbell KJ, Perkins ND. p53- and Mdm2-Independent Repression of NF-κB Transactivation by the ARF Tumor Suppressor. Molecular Cell. 2003;12(1):15–25.
26. Shao J, Fujiwara T, Kadowaki Y, Fukazawa T, Waku T, Itoshima T, et al. Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene. 2000;19(6):726–36.
27. Lowe JM, Menendez D, Bushel PR, Shatz M, Kirk EL, Troester MA, et al. p53 and NF-κB coregulate proinflammatory gene responses in human macrophages. Cancer Res. 2014;74(8):2182–
28. Schneider, G., Henrich, A., Greiner, G. et al. Cross talk between stimulated NF-κB and the tumor suppressor p53. Oncogene. 2010;29(19):2795–806.
29. Carrà G, Lingua MF, Maffeo B, Taulli R, Morotti A. P53 vs NF-κB: the role of nuclear factor-kappa B in the regulation of p53 activity and vice versa. Cell Mol Life Sci. 2020;77(22):4449–58.
30. Lee YK, Yi EY, Park SY, Jang WJ, Han YS, Jegal ME, et al. Mitochondrial dysfunction suppresses p53 expression via calcium- mediated nuclear factor-kB signaling in HCT116 human colorectal carcinoma cells. BMB Rep. 2018;51(6):296–301. 108 Kumar and Biswas / Indian Journal of Pathology and Oncology 2025;12(2):103–108
31. Fujioka S, Schmidt C, Sclabas GM, Li Z, Pelicano H, Peng B, et al. Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. J Biol Chem. 2004;279(26):27549–59.
32. Ferris RL, Grandis JR. NF- B Gene Signatures and p53 Mutations in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2007;13(19):5663–4.
33. Zhu BS, Xing CG, Lin F, Fan XQ, Zhao K, Qin ZH. Blocking NF- κB nuclear translocation leads to p53-related autophagy activation and cell apoptosis. World J Gastroenterol. 2011;17(4):478–87.
34. Webster GA, Perkins ND. Transcriptional cross talk between NF- kappaB and p53. Mol Cell Biol. 1999;19(5):3485–95.
35. Dey A, Wong E, Cheok C, Tergaonkar V, Lane DP. R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ. 2008;15(2):263–73.
36. Takada Y, Aggarwal BB. Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem. 2004;279(6):4750–9.
37. Anwesha Dey, Wong ET, Bist P, Tergaonkar V, Lane D. Nutlin-3 inhibits the NFκB Pathway in a p53 Dependent Manner: Implications in Lung Cancer Therapy. Cell Cycle. 2007;6:(17):2178–85.
38. [Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, et al. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med. 2011;3(95):95ra74.
39. Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, et al. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappa B and p53 pathways. Oncogene. 2009;28;1151–61.
40. Jung D, Khurana A, Roy D, Kalogera E, Bakkum-Gamez J, Chien J. et al. Quinacrine upregulates p21/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer. Sci Rep. 2018;8(1):2487.